Tertiapin q

Stock solutions of 5-CT, BaCl₂, tertiapin-Q, SCH23390 [(R)-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride] were prepared in water and those of SCH28080 (2-Methyl-8-(phenylmethoxy)imidazo[1,2-a]pyridine-3-acetonitrile) and U73343 (1-[6-[[(17β)-3-Methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-2,5-pyrrolidinedione) in DMSO. All stock solutions, which were at least a thousand times the highest experimental concentration, were aliquoted and stored at -20°C until use. The highest experimental concentration of DMSO was 0.05%. 5-CT, SCH23390 and U73343 were purchased from Tocris (Tocris Bioscience, Bristol, UK); SCH28080 from HelloBio (Bristol, UK); CGP-55845; D-AP5, SR-95531, NBQX from Abcam (Cambridge, U.K.); tertiapin-Q from Abcam and Tocris; Isoflurane from Baxter S.p.A. (Rome, Italy); HEPES, ATP and DMSO from Fluka (St. Gallen, Switzerland). All other substances were obtained from Sigma-Aldrich (Milano, Italy)

In effort to identify the mechanism of SNAG-mGluR2 signaling in RGCs, we applied either 5 µM LY341495 (Tocris) or 300 nM Tertiapin-Q (Abcam) or 1 mM barium (Sigma) or 500 nM linopirdine (Sigma) or 50 µM ivabradine (Sigma) into the MEA recording bath. Additionally, concentrations of 150 uM pertussis toxin (PTX) were injected into the eye, 24 h later the eyes were removed and recorded from using the procedures described above. For wt retina expressing SNAP-mGluR2, the addition of 50µM L-AP4 (Sigma), and and 1 µM ACET (Tocris) was applied to the perfusion in order to block photoreceptor mediated responses.